ANR
Anatara Lifesciences Ltd
Director Trades
| Date | Director | Value |
|---|---|---|
| D. Brookes | $25,000 | |
| J. Michailidis | $5,000 |
Company News
Anatara Lifesciences on track with recruitment for Stage 2 of GaRP IBS trial
Anatara Lifesciences (ASX: ANR) has reported that recruitment for Stage 2 of its pivotal GaRP (Gastrointestinal ReProgramming) trial for the treatment of irritable bowel syndrome (IBS) is proceeding well and remains on budget. The company has also confirmed an extension to the recruitment timeline through to August. Stage 2 of the GaRP trial follows the […]
Anatara Lifesciences’ Stage 2 GaRP trial for IBS treatment gains momentum
Recruitment is advancing for Stage 2 of Anatara Lifesciences’ (ASX: ANR) pivotal gastrointestinal reprogramming (GaRP) trial to treat irritable bowel syndrome (IBS). The five trial sites in Melbourne, Sydney and Brisbane have received more than 500 expressions of interest and have completed the standard screening processes consistent with Stage 1. Thirteen participants have been enrolled […]
Anatara Lifesciences embarks on Stage 2 of GaRP trial for treatment of irritable bowel syndrome
Anatara Lifesciences (ASX: ANR) has initiated Stage 2 of a Phase II gastrointestinal re-programming (GaRP) trial to treat patients with irritable bowel syndrome (IBS). The milestone follows “highly encouraging” findings from Stage 1 of the trial, whereby 61 intent-to-treat participants were given low- and high-dose regimens of the medication. Stage 1 of the trial was […]
Market wrap: share market searching for a new theory as interest rate cuts evaporate
Investors are scrambling around looking for a new investment thesis after the long-awaited prospect of global official interest rate cuts continued to fade out of view. A combination of stubbornly resurgent inflation in the United States, the potentially worsening war in the Middle East and the prospect of a US election campaign all contributed to […]
IBS awareness month: Anatara Lifesciences trial offers hope for millions
Irritable bowel syndrome (IBS) is well-named, many sufferers are unaware of why they are feeling so uncomfortable and it can lead to many years of unhappiness. It is estimated that between 5% to 10% of the world’s population may currently be suffering from IBS, many of whom may be unaware of what the issue is. […]
Anatara Lifesciences opens GaRP therapy trial extension to treat irritable bowel syndrome
Anatara Lifesciences (ASX: ANR) is inviting members of the public to register their interest in Stage 2 of a pivotal Phase II Australian clinical trial of their gastrointestinal reprogramming (GaRP) product in the treatment of irritable bowel syndrome (IBS). The company anticipates strong interest in the double-blind trial to be conducted at five sites in […]
Anatara Lifesciences secures Zoetis catalyst for its novel Detach product
Biotechnology company Anatara Lifesciences (ASX: ANR) has teamed up with animal health developer Zoetis Inc. to develop, manufacture and distribute its Detach product. The news is significant given that Zoetis has over 60 years’ experience in the sector and currently derives almost two thirds of its US$5.3 billion annual revenue from farm animal health products. […]
